## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/851,614	05/08/2001	Yashwant M. Deo	CDJ-166RCE2 4957	
959 7590 01/04/2008 LAHIVE & COCKFIELD, LLP			EXAMINER	
ONE POST OF	FICE SQUARE		EWOLDT, GERALD R	
BOSTON, MA 02109-2127			ART UNIT	PAPER NUMBER
			1644	
			MAIL DATE	DELIVERY MODE
			01/04/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

<u> </u>		Application No.	Applicant(s)				
Office Action Summary		09/851,614	DEO ET AL.				
		Examiner	Art Unit				
		G. R. Ewoldt, Ph.D.	1644				
	The MAILING DATE of this communication appears on the cover sheet with the correspondence address						
Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS,							
WHIC - Exten after S - If NO - Failur Any re	HEVER IS LONGER, FROM THE MAILING DA sions of time may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. period for reply is specified above, the maximum statutory period w e to reply within the set or extended period for reply will, by statute, eply received by the Office later than three months after the mailing d patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATION 36(a). In no event, however, may a reply be tin vill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).				
Status			•				
1)⊠	Responsive to communication(s) filed on 24 Oc	<u>ctober 2007</u> .					
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ This action is non-final.						
•—	- · · · · · · · · · · · · · · · · · · ·						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.							
Disposition	on of Claims	·					
4)⊠ Claim(s) <u>99 and 108-111</u> is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
•	6)⊠ Claim(s) <u>99 and 108-111</u> is/are rejected.						
•	Claim(s) is/are objected to. Claim(s) are subject to restriction and/or	r election requirement	• .				
<u>ا</u> ره	oralin(s) are subject to restriction and or	·					
Application Papers							
,	The specification is objected to by the Examine						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
,	·						
•	nder 35 U.S.C. § 119						
12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
3. Copies of the certified copies of the priority documents have been received in this National Stage							
application from the International Bureau (PCT Rule 17.2(a)).							
* See the attached detailed Office action for a list of the certified copies not received.							
	•						
Attachment	t(s)	•					
	e of References Cited (PTO-892)	4) Interview Summary Paper No(s)/Mail Da					
3) Inform	e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO/SB/08) r No(s)/Mail Date	5) Notice of Informal P					

Application/Control Page 2 Number: 09/851,614

Art Unit: 1644

## DETAILED ACTION

1. A request for continued examination (RCE) under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed 10/24/07 in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's amendment and remarks and filed 10/24/07 have been entered.

- 2. Claims 99 and 108-111 are pending.
- 3. In view of Applicant's amendments all previous rejections have been withdrawn.
- 4. The following are new grounds for rejection.
- 5. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

6. Claims 108-111 are rejected under 35 U.S.C. § 112, first paragraph, as the specification does not contain a written description of the claimed invention, in that the disclosure does not reasonably convey to one skilled in the relevant art that the inventor(s) had possession of the claimed invention at the time the application was filed. This is a new matter rejection.

The specification and the claims as originally filed do not provide support for the invention as now claimed, specifically, the antibody of any of Claims 108-110 and thus also the antibody of Claim 111 which depends from Claims 108-111.

Regarding the antibodies of Claims 108-110, Applicant cites Figure 13 and original Claim 51.

Number: 09/851,614 Art Unit: 1644

Claim 51 supports only an antibody comprising both SEQ ID NO:2 and SEQ ID NO:4, not an antibody comprising SEQ ID NO:2 or SEQ ID NO:4 as claimed. Figure 13 discloses only the protein sequences of the B11 variable chains. More specifically regarding Claim 110, original Claim 51 supports a human antibody but not any antibody comprising both SEQ ID NO:2 and SEQ ID NO:4.

- Claim 99 is allowed. 7.
- Any inquiry concerning this communication or earlier communications from the examiner should be directed to Dr. Gerald Ewoldt whose telephone number is (571) 272-0843. The examiner can normally be reached Monday through Thursday from 7:30 am to 5:30 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841.
- Please Note: Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197.

G.R. Ewoldt, Ph.D. Primary Examiner

Technology Center 1600